Livia Archibugi1, Paolo Giorgio Arcidiacono1, Gabriele Capurso2. 1. Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy. 2. Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy. Electronic address: capurso.gabriele@hsr.it.
Abstract
BACKGROUND: Previous studies investigating the association between statin use and pancreatic cancer (PDAC) risk for a possible chemopreventive effect gathered heterogeneous results. AIMS: To conduct a systematic review and meta-analysis to clarify this association. METHODS: Comprehensive literature search of articles published up to February 2018, including case-control (CC),cohort studies (C), randomized controlled trials (RCTs) assessing association between statin use and PDAC risk. Studies had to report odds ratio (OR)/relative risk (RR), estimates with 95% confidence interval (CI), or provide data for their calculation. Pooled ORs with 95%CIs were calculated using random effects model, publication bias through Begg and Mazumdar test and heterogeneity by I2 value. RESULTS: 27 studies(13 CC, 9C, 5 RCTs) for a total population of 11,975 PDAC/3,433,175 controls contributed to the analysis. The overall pooled result demonstrated a reduced PDAC risk among statin users (OR 0.70; 95% CI 0.60-0.82; p < 0.0001), compared to non-users. Sensitivity analyses suggested the risk reduction to be more important in CC studies, studies conducted in Asia and Europe, in males and atorvastatin users. No publication bias found. CONCLUSIONS: The present meta-analysis suggests that statin use is associated with an overall PDAC risk reduction of 30%. Further studies are needed to clarify the association.
BACKGROUND: Previous studies investigating the association between statin use and pancreatic cancer (PDAC) risk for a possible chemopreventive effect gathered heterogeneous results. AIMS: To conduct a systematic review and meta-analysis to clarify this association. METHODS: Comprehensive literature search of articles published up to February 2018, including case-control (CC),cohort studies (C), randomized controlled trials (RCTs) assessing association between statin use and PDAC risk. Studies had to report odds ratio (OR)/relative risk (RR), estimates with 95% confidence interval (CI), or provide data for their calculation. Pooled ORs with 95%CIs were calculated using random effects model, publication bias through Begg and Mazumdar test and heterogeneity by I2 value. RESULTS: 27 studies(13 CC, 9C, 5 RCTs) for a total population of 11,975 PDAC/3,433,175 controls contributed to the analysis. The overall pooled result demonstrated a reduced PDAC risk among statin users (OR 0.70; 95% CI 0.60-0.82; p < 0.0001), compared to non-users. Sensitivity analyses suggested the risk reduction to be more important in CC studies, studies conducted in Asia and Europe, in males and atorvastatin users. No publication bias found. CONCLUSIONS: The present meta-analysis suggests that statin use is associated with an overall PDAC risk reduction of 30%. Further studies are needed to clarify the association.
Authors: Jin Ho Choi; Sang Hyub Lee; Gunn Huh; Jung Won Chun; Min Su You; Woo Hyun Paik; Ji Kon Ryu; Yong-Tae Kim Journal: Cancer Med Date: 2019-10-21 Impact factor: 4.452
Authors: Tobiloba E Oni; Giulia Biffi; Lindsey A Baker; Yuan Hao; Claudia Tonelli; Tim D D Somerville; Astrid Deschênes; Pascal Belleau; Chang-Il Hwang; Francisco J Sánchez-Rivera; Hilary Cox; Erin Brosnan; Abhishek Doshi; Rebecca P Lumia; Kimia Khaledi; Youngkyu Park; Lloyd C Trotman; Scott W Lowe; Alexander Krasnitz; Christopher R Vakoc; David A Tuveson Journal: J Exp Med Date: 2020-09-07 Impact factor: 14.307
Authors: Madeleine Dorsch; Manuela Kowalczyk; Mélanie Planque; Geronimo Heilmann; Sebastian Urban; Philip Dujardin; Jan Forster; Kristina Ueffing; Silke Nothdurft; Sebastian Oeck; Annika Paul; Sven T Liffers; Farnusch Kaschani; Markus Kaiser; Alexander Schramm; Jens T Siveke; Monte M Winslow; Sarah-Maria Fendt; Perihan Nalbant; Barbara M Grüner Journal: Cell Rep Date: 2021-11-23 Impact factor: 9.423